Business
ASCO abstracts for SRA737 published
ASCO abstracts for SRA737 published.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 1927Z Sareum Holdings PLC 16 May 2019 \n\n(AIM: SAR) 16 May 2019\n \nSareum Holdings PLC\n(\"Sareum\" or the \"Company\")\n \nSareum notes that Sierra Oncology has provided an update on its clinical data presentations at ASCO 2019 with SRA737 (a Chk1 inhibitor) in subjects with advanced cancer \nSareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, notes that Sierra Oncology (the licence holder for Chk1 inhibitor SRA737) has provided further information relating to presentations of preliminary clinical data from its Phase 1/2 SRA737 monotherapy study and its Phase 1/2 study of SRA737 in combination with low dose gemcitabine (SRA737+LDG) at the upcoming 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, USA (31 May-4 June 2019).\n \nTwo abstracts (published late yesterday) will be presented in poster presentations on Saturday, 1 June.\n \nASCO 2019 Poster Presentations\n \nTitle: A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer\nAbstract: 3094\nPoster #: 86\nPoster Session: Developmental Therapeutics and Tumor Biology (Nonimmuno) \nDate and Time: Saturday, 1 June, 8:00 - 11:00 am CT\nLocation: McCormick Place, Event room: Hall A\n \nThe published abstract can be accessed by clicking here and its conclusions are as follows:\n \nIn this first-in-human trial of SRA737 monotherapy, the MTD (maximum tolerated dose) was 1000 mg/day and based on overall to...